Birdwatch Note Rating
2021-11-14 13:33:46 UTC - SOMEWHAT_HELPFUL
Rated by Participant: E9FA3618E5EF5961394CD4D435DC2E992A6071E7CE9DA8B0D2776210EB1164CA
Participant Details
Original Note:
Regeneron, one of the few FDA emergency-authorized treatment drugs, was in short supply since its authorized used started in November 2020. There was not enough production to keep up with the COVID-19 hospitalization demand. https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms-f/u-s-fda-grants-emergency-use-authorization-to-regeneron-covid-19-antibody-given-to-trump-idUSKBN28201L https://www.forbes.com/sites/jemimamcevoy/2021/09/10/nation-short-on-supply-of-key-covid-treatment-desperate-states-told-to-reduce-requests/?sh=7476ed026737
All Note Details